Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

199 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

Adverse Events Week 38 Mepolizumab HES NCT00086658 - Adverse Events Week 38

- 15/07/2017 - 1 Formulário, 1 Grupo de itens, 1 Elemento de dados, 1 Idioma
Grupo de itens: Adverse Events
Study part: Adverse Events Week 38/ Early Withdrawal visit. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 32 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 32

- 12/07/2017 - 1 Formulário, 1 Grupo de itens, 1 Elemento de dados, 1 Idioma
Grupo de itens: Corticosteroid Medication
Study part: Corticosteroid Medication Week 32. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Concomitant Medications Week 32 Mepolizumab HES NCT00086658 - Concomitant Medications Week 32

- 12/07/2017 - 1 Formulário, 1 Grupo de itens, 1 Elemento de dados, 1 Idioma
Grupo de itens: Concomitant Medications
Study part: Concomitant Medications Week 32. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Pharmacokinetics- Blood Week 32 Mepolizumab HES NCT00086658 - Pharmacokinetics- Blood Week 32

- 12/07/2017 - 1 Formulário, 1 Grupo de itens, 5 Elementos de dados, 1 Idioma
Grupo de itens: Pharmacokinetics Blood
Study part: Pharmacokinetics- Blood Week 32. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Investigational Product – IV Dosing Week 32 Mepolizumab HES NCT00086658 - Investigational Product – IV Dosing Week 32

- 12/07/2017 - 1 Formulário, 1 Grupo de itens, 6 Elementos de dados, 1 Idioma
Grupo de itens: Investigational Product Dose Intravenous
Study part: Investigational Product – IV Dosing Week 32. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Vital Signs Post- Infusion Week 32 Mepolizumab HES NCT00086658 - Vital Signs Post- Infusion Week 32

- 12/07/2017 - 1 Formulário, 1 Grupo de itens, 7 Elementos de dados, 1 Idioma
Grupo de itens: VITAL SIGNS
Study part: Vital Signs Post- Infusion Week 32.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Vital Signs Pre- Infusion Week 32 Mepolizumab HES NCT00086658 - Vital Signs Pre- Infusion Week 32

- 12/07/2017 - 1 Formulário, 1 Grupo de itens, 8 Elementos de dados, 1 Idioma
Grupo de itens: VITAL SIGNS
Study part: Vital Signs Pre- Infusion Week 32.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 32 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 32

- 12/07/2017 - 1 Formulário, 1 Grupo de itens, 5 Elementos de dados, 1 Idioma
Grupo de itens: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 32.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Urine Pregnancy Test Prompt Week 32 Mepolizumab HES NCT00086658 - Urine Pregnancy Test Prompt Week 32

- 12/07/2017 - 1 Formulário, 1 Grupo de itens, 2 Elementos de dados, 1 Idioma
Grupo de itens: Urine Pregnancy Test
Study part: Urine Pregnancy Test Prompt Week 32. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Central Laboratory –Blood Week 32 Mepolizumab HES NCT00086658 - Central Laboratory –Blood Week 32

- 12/07/2017 - 1 Formulário, 1 Grupo de itens, 2 Elementos de dados, 1 Idioma
Grupo de itens: Central laboratory
Study part: Central Laboratory –Blood Week 32. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Adverse Events Week 32 Mepolizumab HES NCT00086658 - Adverse Events Week 32

- 12/07/2017 - 1 Formulário, 1 Grupo de itens, 1 Elemento de dados, 1 Idioma
Grupo de itens: Adverse Events
Study part: Adverse Events Week 32. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Investigational Product – IV Dosing Week 28 Mepolizumab HES NCT00086658 - Investigational Product – IV Dosing Week 28

- 12/07/2017 - 1 Formulário, 1 Grupo de itens, 6 Elementos de dados, 1 Idioma
Grupo de itens: Investigational Product Dose Intravenous
Study part: Investigational Product – IV Dosing Week 28. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial